Blog

  1. Chinese antibody market powers ahead

    Today we return to our first ever data report, released three years ago, when we claimed that China was a market no supplier could ignore, and we look at new data to see whether our predictions came true. Back in 2014 we stated that ‘the data suggests that China is set to claim the lion’s […]

  2. New team members at CiteAb

    We’re excited to be welcoming three new people to the CiteAb team – two product managers and a developer. Alicia Cooper and Rebecca Sadler join us as product managers as CiteAb continues to grow and offer ever more complex data sets and market reports. Rebecca graduates from her biology degree at the University of Bath […]

  3. First look at the global chemical probes market

      We recently announced that our team here at CiteAb has expanded our platform to cover multiple reagent types, and today we’re taking a first look at some of our new data. The inhibitors and activators used by life scientists to investigate cellular processes are collectively termed as ‘chemical probes’. They provide vital tools for […]

  4. We’re working with the GBSI to improve ICC antibody validation

    Our founder, Dr Andrew Chalmers, is leading an Antibody Validation Working Group for the Global Biological Standards Institute (GBSI) focused on improving the validation of antibodies used for ICC. The group is one of nine created by the GBSI with the aim of creating a series of antibody validation guidelines for each of the most […]

  5. What are the most important antibody targets for immunocytochemistry?

    New to our series of blogs on antibody research applications, today we are exploring the top targets for ICC, or immunocytochemistry. ICC is the staining and microscopic examination of cells, which are often grown in culture. This is not to be confused with immunohistochemistry (IHC), which involves the staining of tissues with their normal organisation […]

  6. CiteAb: now more than just antibodies!

    Here at CiteAb we have recently developed our technology so that we can now collate data on multiple reagent types – not just antibodies. This means we can now give a picture of the global market for different types of reagent, in the same way that we have for antibodies. Our founder, Dr Andrew Chalmers, […]

  7. Which antibodies for zebrafish are the most used?

    As the vast majority of commercial antibodies are raised against human proteins, we became interested in taking a look at which commercial antibodies are being used by the zebrafish research community. Is the zebrafish research community using a subset of specialist antibodies raised for zebrafish research, or is it relying on anti-human antibodies cross reacting? […]

  8. Reporting from Alpbach – three ways to validate antibodies

    Last week our founder Dr Andrew Chalmers was in Alpbach for the 8th Affinity Proteomics Meeting, where he presented CiteAb’s latest antibody validation efforts. At the event a huge range of antibody and proteomics science was presented, ranging from exciting new new binders to antibody engineering and therapeutics. Andrew said: “Over the course of the […]

  9. We’re recruiting! Graduate developer wanted to join our team.

        THE DEADLINE FOR APPLICATIONS HAS NOW CLOSED     Here at CiteAb we’re looking for a graduate in Computer Science to join our team and help to develop our industry leading data curation, machine learning and search engine technology. Job title: Graduate Developer Location: Bath Salary: Starting £22 – £27k Hours: Full Time. Part […]

  10. We’re recruiting! Biologist or Chemist wanted to join our team.

        THE DEADLINE FOR APPLICATIONS HAS NOW CLOSED     Here at CiteAb we’re looking for a graduate in biological sciences or chemistry to join our team and manage some of our key data products. Job title: Data product manager (Biological Sciences or Chemistry) Location: Bath Salary: Competitive (Based on qualifications and experience) Hours: Full […]